210 related articles for article (PubMed ID: 34380502)
21. Altered editing in RNA editing adenosine deaminase ADAR2 gene transcripts of systemic lupus erythematosus T lymphocytes.
Laxminarayana D; O'Rourke KS; Maas S; Olorenshaw I
Immunology; 2007 Jul; 121(3):359-69. PubMed ID: 17376196
[TBL] [Abstract][Full Text] [Related]
22. SRSF9 selectively represses ADAR2-mediated editing of brain-specific sites in primates.
Shanmugam R; Zhang F; Srinivasan H; Charles Richard JL; Liu KI; Zhang X; Woo CWA; Chua ZHM; Buschdorf JP; Meaney MJ; Tan MH
Nucleic Acids Res; 2018 Aug; 46(14):7379-7395. PubMed ID: 29992293
[TBL] [Abstract][Full Text] [Related]
23. Programmable C-to-U RNA editing using the human APOBEC3A deaminase.
Huang X; Lv J; Li Y; Mao S; Li Z; Jing Z; Sun Y; Zhang X; Shen S; Wang X; Di M; Ge J; Huang X; Zuo E; Chi T
EMBO J; 2020 Nov; 39(22):e104741. PubMed ID: 33058229
[TBL] [Abstract][Full Text] [Related]
24. irCLASH reveals RNA substrates recognized by human ADARs.
Song Y; Yang W; Fu Q; Wu L; Zhao X; Zhang Y; Zhang R
Nat Struct Mol Biol; 2020 Apr; 27(4):351-362. PubMed ID: 32203492
[TBL] [Abstract][Full Text] [Related]
25. Base-pairing probability in the microRNA stem region affects the binding and editing specificity of human A-to-I editing enzymes ADAR1-p110 and ADAR2.
Ishiguro S; Galipon J; Ishii R; Suzuki Y; Kondo S; Okada-Hatakeyama M; Tomita M; Ui-Tei K
RNA Biol; 2018; 15(7):976-989. PubMed ID: 29950133
[TBL] [Abstract][Full Text] [Related]
26. ADAR2 A-->I editing: site selectivity and editing efficiency are separate events.
Källman AM; Sahlin M; Ohman M
Nucleic Acids Res; 2003 Aug; 31(16):4874-81. PubMed ID: 12907730
[TBL] [Abstract][Full Text] [Related]
27. Identification of widespread ultra-edited human RNAs.
Carmi S; Borukhov I; Levanon EY
PLoS Genet; 2011 Oct; 7(10):e1002317. PubMed ID: 22028664
[TBL] [Abstract][Full Text] [Related]
28. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD.
Moore S; Alsop E; Lorenzini I; Starr A; Rabichow BE; Mendez E; Levy JL; Burciu C; Reiman R; Chew J; Belzil VV; W Dickson D; Robertson J; Staats KA; Ichida JK; Petrucelli L; Van Keuren-Jensen K; Sattler R
Acta Neuropathol; 2019 Jul; 138(1):49-65. PubMed ID: 30945056
[TBL] [Abstract][Full Text] [Related]
29. Site-directed RNA editing by adenosine deaminase acting on RNA for correction of the genetic code in gene therapy.
Azad MTA; Bhakta S; Tsukahara T
Gene Ther; 2017 Dec; 24(12):779-786. PubMed ID: 28984845
[TBL] [Abstract][Full Text] [Related]
30. Adenosine to inosine editing by ADAR2 requires formation of a ternary complex on the GluR-B R/G site.
Jaikaran DC; Collins CH; MacMillan AM
J Biol Chem; 2002 Oct; 277(40):37624-9. PubMed ID: 12163487
[TBL] [Abstract][Full Text] [Related]
31. Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications.
Tang T; Han Y; Wang Y; Huang H; Qian P
Front Cell Dev Biol; 2021; 9():677587. PubMed ID: 34386490
[TBL] [Abstract][Full Text] [Related]
32. Comparative Activity of Adenosine Deaminase Acting on RNA (ADARs) Isoforms for Correction of Genetic Code in Gene Therapy.
Azad MTA; Qulsum U; Tsukahara T
Curr Gene Ther; 2019; 19(1):31-39. PubMed ID: 30426900
[TBL] [Abstract][Full Text] [Related]
33. Deciphering the principles of the RNA editing code via large-scale systematic probing.
Uzonyi A; Nir R; Shliefer O; Stern-Ginossar N; Antebi Y; Stelzer Y; Levanon EY; Schwartz S
Mol Cell; 2021 Jun; 81(11):2374-2387.e3. PubMed ID: 33905683
[TBL] [Abstract][Full Text] [Related]
34. Analysis and minimization of cellular RNA editing by DNA adenine base editors.
Rees HA; Wilson C; Doman JL; Liu DR
Sci Adv; 2019 May; 5(5):eaax5717. PubMed ID: 31086823
[TBL] [Abstract][Full Text] [Related]
35. C-to-U RNA Editing: A Site Directed RNA Editing Tool for Restoration of Genetic Code.
Bhakta S; Tsukahara T
Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140804
[TBL] [Abstract][Full Text] [Related]
36. Adenosine Deaminase That Acts on RNA 3 (ADAR3) Binding to Glutamate Receptor Subunit B Pre-mRNA Inhibits RNA Editing in Glioblastoma.
Oakes E; Anderson A; Cohen-Gadol A; Hundley HA
J Biol Chem; 2017 Mar; 292(10):4326-4335. PubMed ID: 28167531
[TBL] [Abstract][Full Text] [Related]
37. Structure and sequence determinants required for the RNA editing of ADAR2 substrates.
Dawson TR; Sansam CL; Emeson RB
J Biol Chem; 2004 Feb; 279(6):4941-51. PubMed ID: 14660658
[TBL] [Abstract][Full Text] [Related]
38. Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression.
Han J; An O; Hong H; Chan THM; Song Y; Shen H; Tang SJ; Lin JS; Ng VHE; Tay DJT; Molias FB; Pitcheshwar P; Tan HQ; Yang H; Chen L
Sci Adv; 2020 Jun; 6(25):eaba5136. PubMed ID: 32596459
[TBL] [Abstract][Full Text] [Related]
39. RNA editing by ADAR2 is metabolically regulated in pancreatic islets and beta-cells.
Gan Z; Zhao L; Yang L; Huang P; Zhao F; Li W; Liu Y
J Biol Chem; 2006 Nov; 281(44):33386-94. PubMed ID: 16956888
[TBL] [Abstract][Full Text] [Related]
40. The RNA editing enzymes ADARs: mechanism of action and human disease.
Tomaselli S; Locatelli F; Gallo A
Cell Tissue Res; 2014 Jun; 356(3):527-32. PubMed ID: 24770896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
